Đặt banner 324 x 100

Hope for Cancer Patients: From Keytruda to Smarter, More Powerful Next-Gen Treatments


Hey everyone in the cancer community – patients, caregivers, survivors – if you're navigating this tough journey, I want to share some real hope that's emerging right now.

Many of us know Keytruda (pembrolizumab) as a lifesaver. It's helped countless people by unleashing the immune system against cancer, and in 2024, it topped global sales at nearly $30 billion. For lung cancer, melanoma, and others, it's brought longer survival and better quality of life.

But let's be real: it's not a miracle for everyone. Response rates often hover around 20-40%, resistance can kick in, and some tumors stay "cold" and hidden from the immune attack. We've all felt that frustration when progress plateaus.

The exciting part? The next generation of immunotherapies is here, tackling these exact limits head-on. These aren't just tweaks – they're engineered upgrades:

  • PD-1/VEGF bispecific antibodies (like AK112 from Akeso) hit two targets at once: boosting immunity while cutting off the tumor's blood supply and immunosuppression. Early data shows higher response rates and better progression-free survival.
  • Bispecific antibodies and immune ADCs (antibody-drug conjugates) deliver precise, multi-angle strikes – combining immune activation with direct cancer-killing payloads.

Chinese innovative biotechs are leading this charge with advanced molecular engineering, and their breakthroughs are going global through partnerships.

For us patients, this means potential for deeper, longer-lasting responses – even after first-gen treatments like Keytruda start to fade.

Companies like HK DengYueMed are playing a key role too, committed to quality, compliance, and getting these advanced therapies to patients worldwide faster, improving access and options.

Cancer fights hard, but so does science – and it's accelerating. We're entering a new era of smarter, more effective treatments.

Stay strong, share your stories, and hold onto hope. If you're on immunotherapy or exploring next options, you're not alone.

What's your experience been like? Comment below – let's support each other.

Thông tin liên hệ


: Dengyuemed
: HONG KONG DENGYUE PHARMACEUTICAL CO., LIMITED
: 85252881999
: